Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer

Trial Profile

An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Foresee Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2018 This trial has been completed in Lithuania (End date: 2018-11-19)according to European Clinical Trials Database record.
    • 06 Dec 2018 This trial has been completed in Czech Republic according to European Clinical Trials Database record.
    • 26 Nov 2018 According to a Foresee Pharmaceuticals media release,Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top